Skip to main content
Premium Trial:

Request an Annual Quote

Bayer-Genzyme Deal Yields Access to Small-Molecule Library

Premium

LEVERKUSEN, Germany--Bayer here has announced a collaboration with Genzyme to accelerate identification of drug development targets. Candidates will come from Genzyme's small-molecule compound library and be analyzed with Bayer's high-speed robotic screening equipment. The deal could be worth as much as $35 million to Genzyme in fees and milestone payments, the company said.

Terms of the collaboration include an up-front payment to Genzyme for access to the company's library, with milestone payments coming as selected compounds proceed through clinical trials. "The unique chemistry technology developed by Genzyme is an ideal combination with Bayer's expertise in high-technology robotic screening methods," commented Wolfgang Hartwig, Bayer's head of worldwide pharmaceutical research.

Filed under

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.